Novo Nordisk A S (NONOF) stock
NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$38.24−0.60 (-1.53%)
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Novo Nordisk A S's total debt was 142.98B DKK at Dec 31, 2025. For fiscal 2025 it was 142.98B DKK, up 23.4% from the year before. The highest annual figure on record is 142.98B DKK in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 142.98B DKK | +23.4% |
| FY2024 | Dec 31, 2024 | 115.90B DKK | +246.1% |
| FY2023 | Dec 31, 2023 | 33.48B DKK | +22.9% |
| FY2022 | Dec 31, 2022 | 27.25B DKK | -32.4% |
| FY2021 | Dec 31, 2021 | 40.33B DKK | +126.4% |
| FY2020 | Dec 31, 2020 | 17.82B DKK | +199.1% |
| FY2019 | Dec 31, 2019 | 5.96B DKK | +478.3% |
| FY2018 | Dec 31, 2018 | 1.03B DKK | -39.2% |
| FY2017 | Dec 31, 2017 | 1.69B DKK | +639.7% |
| FY2016 | Dec 31, 2016 | 229.00M DKK | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | 142.98B DKK | +254.5% |
| Q4 FY2024 | Dec 31, 2024 | 115.90B DKK | +550.6% |
| Q4 FY2023 | Dec 31, 2023 | 33.48B DKK | +462.1% |
| Q4 FY2022 | Dec 31, 2022 | 27.25B DKK | +2545.6% |
| Q4 FY2021 | Dec 31, 2021 | 40.33B DKK | +2280.7% |
| Q4 FY2020 | Dec 31, 2020 | 17.82B DKK | +7679.5% |
| Q4 FY2019 | Dec 31, 2019 | 5.96B DKK | – |
| Q4 FY2018 | Dec 31, 2018 | 1.03B DKK | – |
| Q4 FY2017 | Dec 31, 2017 | 1.69B DKK | – |
| Q4 FY2016 | Dec 31, 2016 | 229.00M DKK | – |
See a number that looks wrong?